Oct 10, 2025 · Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Includes Libtayo side effects, …

Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, & as an adjuvant treatment for high-risk CSCC. Review Important Safety Info & Full Prescribing Information …

LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6.

Oct 1, 2024 · Find patient medical information for Libtayo (cemiplimab-rwlc) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

Nov 6, 2024 · Libtayo (Cemiplimab-rwlc Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health …

On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma ...

An unusual or allergic reaction to cemiplimab, other medications, foods, dyes, or preservatives Pregnant or trying to get pregnant Breastfeeding How should I use this medication? This medication is infused …

LIBTAYO® (Lib-TIE-oh) (cemiplimab-rwlc) injection What is the most important information I should know about LIBTAYO? LIBTAYO is a medicine that may treat certain types of cancers by working …

Libtayo - Cemiplimab Injection What is this medication? CEMIPLIMAB (se MIP li mab) treats skin cancer and lung cancer. It works by helping your immune system slow or stop the spread of cancer cells. It …

Nov 24, 2025 · Cemiplimab Generic name: cemiplimab [ se-MIP-li-mab ] Brand name: Libtayo Dosage form: intravenous solution (rwlc 350 mg/7 mL) Drug class: Anti-PD-1 and PD-L1 monoclonal …